Genetic barrier to antiretroviral drug-resistance;Barrière génétique À la résistance des antirétroviraux: Le point sur le raltégravir, premier inhibiteur d'intégrase

Medecine et Maladies Infectieuses

Volumn 40, Issue , 2010, Pages S1-S10

  Delaugerre, C ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Concentration; Efavirenz; Lamivudine; Mutation; Protease inhibitors; Raltegravir; Replicative capacity; Resistance; Treatment

Indexed keywords

EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE; 2 PYRROLIDONE DERIVATIVE; INTEGRASE;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG BLOOD LEVEL; GENE MUTATION; GENETIC POLYMORPHISM; PHARMACOGENETICS; VIRUS LOAD; VIRUS REPLICATION; AMINO ACID SUBSTITUTION; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; GENETIC SELECTION; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MUTATION; PATHOGENICITY; PHYSIOLOGY; POINT MUTATION; REVIEW; STRUCTURAL GENE; VIROLOGY; VIRULENCE;

AMINO ACID SUBSTITUTION; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; GENES, POL; GENETIC VARIATION; HIV; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MUTATION; POINT MUTATION; PYRROLIDINONES; SELECTION, GENETIC; VIRULENCE; VIRUS REPLICATION;

EID: 79952108394     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/S0399-077X(10)70001-9     Document Type: Article

References (36)

1. Coutsinos, D., Invernizzi, C.F., Xu, H., Brenner, B.G., Wainberg, M.A., Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 20 (2010), 117–131.
2. Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48 (2004), 4680–4686.
3. King, N.M., Prabu-Jeyabalan, M., Nalivaika, E.A., Wigerinck, P., de Bethune, M.P., Schiffer, C.A., Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 78 (2004), 12012–12021.
4. Margot, N.A., Enejosa, J., Cheng, A.K., Miller, M.D., McColl, D.J., Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 52 (2009), 209–221.
5. Maserati, R., De Silvestri, A., Uglietti, A., Colao, G., Di Biagio, A., Bruzzone, B., et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. Aids 24 (2010), 1013–1018.
6. Perrin, V., Mammano, F., Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J Virol 77 (2003), 10172–10175.
7. Cooper, D.A., Steigbigel, R.T., Gatell, J.M., Rockstroh, J.K., Katlama, C., Yeni, P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359 (2008), 355–365.
8. Fransen, S., Gupta, S., Danovich, R., Hazuda, D., Miller, M., Witmer, M., et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83 (2009), 11440–11446.
9. Quercia, R., Dam, E., Perez-Bercoff, D., Clavel, F., Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 83 (2009), 10245–10249.
10. Hatano, H., Delwart, E.L., Norris, P.J., Lee, T.H., Dunn-Williams, J., Hunt, P.W., et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 83 (2009), 329–335.
11. Malet, I., Delelis, O., Valantin, M.A., Montes, B., Soulie, C., Wirden, M., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52 (2008), 1351–1358.
12. Malet, I., Delelis, O., Soulie, C., Wirden, M., Tchertanov, L., Mottaz, P., et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63 (2009), 795–804.
13. de Meyer, S., Vangeneugden, T., van Baelen, B., de Paepe, E., van Marck, H., Picchio, G., et al. Resistance profile of darunavir:combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24 (2008), 379–388.
14. Delaugerre, C., Flandre, P., Chaix, M.L., Ghosn, J., Raffi, F., Dellamonica, P., et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 53 (2009), 2934–2939.
15. Markowitz, M., Morales-Ramirez, J.O., Nguyen, B.Y., Kovacs, C.M., Steigbigel, R.T., Cooper, D.A., et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43 (2006), 509–515.
16. Murray, J.M., Emery, S., Kelleher, A.D., Law, M., Chen, J., Hazuda, D.J., et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids 21 (2007), 2315–2321.
17. Lennox, J.L., DeJesus, E., Lazzarin, A., Pollard, R.B., Madruga, J.V., Berger, D.S., et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374 (2009), 796–806.
18. th CROI. San Franscisco, USA 2010.
19. Bacheler, L.T., Anton, E.D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44 (2000), 2475–2484.
20. Eron, J.J., Young, B., Cooper, D.A., Youle, M., Dejesus, E., Andrade-Villanueva, J., et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2):two multicentre, double-blind, randomised controlled trials. Lancet 375 (2010), 396–407.
21. Steigbigel RT, Cooper DA, Eron JE, Gatell JM, Kumar PN, Rockstroh JK, et al. 96-week results from BENCHMRK 1 and 2, Phase III studies of raltegravir in patients failing ART with triple-class-resistant. 16th CROI. Montreal, Canada 2009.
22. Yazdanpanah, Y., Fagard, C., Descamps, D., Taburet, A.M., Colin, C., Roquebert, B., et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49 (2009), 1441–1449.
23. th CROI. San Franscisco, USA 2010.
24. Caby, F., Valin, N., Marcelin, A.G., Schneider, L., Andrade, R., Guiguet, M., et al. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scand J Infect Dis 42 (2010), 527–532.
25. Ghosn, J., Mazet, A.A., Avettand-Fenoel, V., Peytavin, G., Wirden, M., Delfraissy, J.F., et al. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother 64 (2009), 433–434.
26. Gallien, S., Delaugerre, C., Hu, Z., Braun, J., Charreau, I., Euphrasie, F., et al. Integrase inhibitor resistance mutations in treatment-experienced HIV-1-infected patients with low-level viraemia receiving raltegravir containing antiretroviral therapy: an ANRS 138-EASIER trial substudy. 2010, International HIV&Hepatitis virus drug resistance workshop & curative strategies, Dubrovnik, Croatia.
27. MacManus, S., Yates, P.J., Elston, R.C., White, S., Richards, N., Snowden, W., GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients:absence of protease resistance at 48 weeks. Aids 18 (2004), 651–655.
28. Rodriguez-French, A., Boghossian, J., Gray, G.E., Nadler, J.P., Quinones, A.R., Sepulveda, G.E., et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 35 (2004), 22–32.
29. Metzner, K.J., Allers, K., Rauch, P., Harrer, T., Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. Aids 21 (2007), 703–711.
30. Brun-Vezinet, F., Descamps, D., Ruffault, A., Masquelier, B., Calvez, V., Peytavin, G., et al. Clinically relevant interpretation of genotype for resistance to abacavir. Aids 17 (2003), 1795–1802.
31. Masquelier, B., Tamalet, C., Montes, B., Descamps, D., Peytavin, G., Bocket, L., et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 9 (2004), 315–323.
32. Marcelin, A.G., Affolabi, D., Lamotte, C., Mohand, H.A., Delaugerre, C., Wirden, M., et al. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. J Med Virol 74 (2004), 16–20.
33. Vora, S., Marcelin, A.G., Gunthard, H.F., Flandre, P., Hirsch, H.H., Masquelier, B., Zinkernagel, A., Peytavin, G., Calvez, V., Perrin, L., Yerly, S., Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. Aids 20 (2006), 35–40.
34. Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Sylte, J., Richards, B., Bernstein, B., et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 7 (2002), 165–174.
35. Masquelier, B., Breilh, D., Neau, D., Lawson-Ayayi, S., Lavignolle, V., Ragnaud, J.M., et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 46 (2002), 2926–2932.
36. De Meyer, S., Lathouwers, E., Dierynck, I., De Paepe, E., Van Baelen, B., Vangeneugden, T., et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. Aids 23 (2009), 1829–1840.